Recipient T-cell receptors and other immune cell receptors (TCRs)

Recipient T-cell receptors and other immune cell receptors refer to the collective group of surface proteins on a host's immune cells that mediate the recognition of foreign antigens, particularly in the context of transplantation and adoptive cell therapy. The T-cell receptor (TCR) is a complex of integral membrane proteins that participate in the activation of T-cells in response to an antigen presented by the major histocompatibility complex (MHC) (Janeway's Immunobiology, 2017). In the setting of organ or hematopoietic stem cell transplantation, these receptors on recipient cells can recognize donor tissues as foreign, leading to graft rejection. Conversely, in Graft-versus-Host Disease (GvHD), donor T-cell receptors recognize recipient tissues as foreign (NCBI, 2023). Therapeutic strategies targeting these receptors or their downstream signaling pathways—such as calcineurin inhibitors or monoclonal antibodies—aim to modulate the immune response to prevent rejection or treat autoimmune conditions. While this term is a broad classification rather than a single molecular entity, it represents a critical focal point for immunosuppressive pharmacology and the management of allogeneic immune responses (PubMed, 2022).

Other names

Host immune receptorsRecipient immune cell receptorsAllo-reactive T-cell receptorsHost T-cell receptor complex

Drugs targeting these receptors or their signaling pathways work by inhibiting T-cell activation, depleting specific immune cell populations, or blocking co-stimulatory signals required for a full immune response. For example, calcineurin inhibitors like cyclosporine interfere with downstream TCR signaling, while monoclonal antibodies like muromonab-CD3 directly bind and block the TCR complex (StatPearls, 2023; NIH, 2024).